<!doctype html><html lang=zh-tw><head><meta charset=utf-8><meta name=description content="at: [[inbox]]
Pulmonology - Chronic Obstructive Pulmonary Disease - Fast Facts | NEJM Resident 360 Chronic obstructive pulmonary disease (COPD) is characterized by persistent expiratory airflow limitation due to destruction of lung parenchyma and decrease in elastic recoil."><meta property="og:title" content><meta property="og:description" content><meta property="og:type" content="website"><meta property="og:url" content><meta property="og:image" content="https://og-mlkgi530p-htlin222.vercel.app/api/blog?templateTitle=Pulmonology - Chronic Obstructive Pulmonary Disease - Fast Facts | NEJM Resident 360"><title>Pulmonology - Chronic Obstructive Pulmonary Disease - Fast Facts | NEJM Resident 360</title><meta name=viewport content="width=device-width,initial-scale=1"><link rel=alternate type=application/rss+xml href=https://www.physician.tw//feed.xml title><link rel="shortcut icon" type=image/png href=https://www.physician.tw//icon.png><link href=https://www.physician.tw/styles.acd6336f837a791cf1889bb120dfb142.min.css rel=stylesheet><link href=https://www.physician.tw/styles/_light_syntax.86a48a52faebeaaf42158b72922b1c90.min.css rel=stylesheet id=theme-link><script src=https://www.physician.tw/js/darkmode.dfadb738e747a87e78c7144d7267f1bc.min.js></script>
<script src=https://www.physician.tw/js/util.6f22941e242efae60fd84e7c32e874fa.min.js></script>
<link rel=preload href=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/katex.min.css as=style onload='this.onload=null,this.rel="stylesheet"' integrity=sha384-R4558gYOUz8mP9YWpZJjofhk+zx0AS11p36HnD2ZKj/6JR5z27gSSULCNHIRReVs crossorigin=anonymous><script defer src=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/katex.min.js integrity=sha384-z1fJDqw8ZApjGO3/unPWUPsIymfsJmyrDVWC8Tv/a1HeOtGmkwNd/7xUS0Xcnvsx crossorigin=anonymous></script>
<script defer src=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/contrib/auto-render.min.js integrity=sha384-+XBljXPPiv+OzfbB3cVmLHf4hdUFHlWNZN5spNQ7rmHTXpd7WvJum6fIACpNNfIR crossorigin=anonymous></script>
<script defer src=https://cdn.jsdelivr.net/npm/katex@0.16.2/dist/contrib/copy-tex.min.js integrity=sha384-ww/583aHhxWkz5DEVn6OKtNiIaLi2iBRNZXfJRiY1Ai7tnJ9UXpEsyvOITVpTl4A crossorigin=anonymous></script>
<script async src=https://unpkg.com/@floating-ui/core@0.7.3></script>
<script async src=https://unpkg.com/@floating-ui/dom@0.5.4></script>
<script async src=https://www.physician.tw/js/popover.f03552ccb84d99ca615d1cfb9abde59e.min.js></script>
<script defer src=https://www.physician.tw/js/code-title.ce4a43f09239a9efb48fee342e8ef2df.min.js></script>
<script defer src=https://www.physician.tw/js/clipboard.2913da76d3cb21c5deaa4bae7da38c9f.min.js></script>
<script defer src=https://www.physician.tw/js/callouts.7723cac461d613d118ee8bb8216b9838.min.js></script>
<script>const SEARCH_ENABLED=!1,LATEX_ENABLED=!0,PRODUCTION=!0,BASE_URL="https://www.physician.tw/",fetchData=Promise.all([fetch("https://www.physician.tw/indices/linkIndex.65a82b7b94ef04bb074516e0838fec90.min.json").then(e=>e.json()).then(e=>({index:e.index,links:e.links})),fetch("https://www.physician.tw/indices/contentIndex.8bcb6773a9d0796ec8f58eee51e8d4e5.min.json").then(e=>e.json())]).then(([{index:e,links:t},n])=>({index:e,links:t,content:n})),render=()=>{const e=new URL(BASE_URL),t=e.pathname,n=window.location.pathname,s=t==n;addCopyButtons(),addTitleToCodeBlocks(),addCollapsibleCallouts(),initPopover("https://www.physician.tw",!0);const o=document.getElementById("footer");if(o){const e=document.getElementById("graph-container");if(!e)return requestAnimationFrame(render);e.textContent="";const t=s&&!1;drawGraph("https://www.physician.tw",t,[{"/moc":"#4388cc"}],t?{centerForce:1,depth:-1,enableDrag:!0,enableLegend:!1,enableZoom:!0,fontSize:.5,linkDistance:1,opacityScale:3,repelForce:1,scale:1.4}:{centerForce:1,depth:1,enableDrag:!0,enableLegend:!1,enableZoom:!0,fontSize:.6,linkDistance:1,opacityScale:3,repelForce:2,scale:1.2})}},init=(e=document)=>{addCopyButtons(),addTitleToCodeBlocks(),renderMathInElement(e.body,{delimiters:[{left:"$$",right:"$$",display:!0},{left:"$",right:"$",display:!1}],macros:{'’':"'"},throwOnError:!1})}</script><script type=module>
    import { attachSPARouting } from "https:\/\/www.physician.tw\/js\/router.9d4974281069e9ebb189f642ae1e3ca2.min.js"
    attachSPARouting(init, render)
  </script></head><body><div id=search-container><div id=search-space><input autocomplete=off id=search-bar name=search type=text aria-label=search placeholder="請輸入像是：hypertension 之類的來看沒有沒什麼有趣的🎳"><div id=results-container></div></div></div><script src=https://cdn.jsdelivr.net/npm/flexsearch@0.7.21/dist/flexsearch.bundle.js integrity="sha256-i3A0NZGkhsKjVMzFxv3ksk0DZh3aXqu0l49Bbh0MdjE=" crossorigin=anonymous defer></script>
<script defer src=https://www.physician.tw/js/full-text-search.e6e2e0c213187ca0c703d6e2c7a77fcd.min.js></script><div class=singlePage><header><h1 id=page-title><a href=https://www.physician.tw/>蜥蜴花園🪴</a></h1><div class=spacer></div><div id=search-icon><p>search</p><svg tabindex="0" aria-labelledby="title desc" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 19.9 19.7"><title id="title">搜尋圖示</title><desc id="desc">打開搜尋圖標</desc><g class="search-path" fill="none"><path stroke-linecap="square" d="M18.5 18.3l-5.4-5.4"/><circle cx="8" cy="8" r="7"/></g></svg></div><div class=darkmode><input class=toggle id=darkmode-toggle type=checkbox tabindex=-1>
<label id=toggle-label-light for=darkmode-toggle tabindex=-1><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" id="dayIcon" viewBox="0 0 35 35" style="enable-background:new 0 0 35 35"><title>明亮模式</title><path d="M6 17.5C6 16.672 5.328 16 4.5 16h-3C.672 16 0 16.672.0 17.5S.672 19 1.5 19h3C5.328 19 6 18.328 6 17.5zM7.5 26c-.414.0-.789.168-1.061.439l-2 2C4.168 28.711 4 29.086 4 29.5 4 30.328 4.671 31 5.5 31c.414.0.789-.168 1.06-.44l2-2C8.832 28.289 9 27.914 9 27.5 9 26.672 8.329 26 7.5 26zm10-20C18.329 6 19 5.328 19 4.5v-3C19 .672 18.329.0 17.5.0S16 .672 16 1.5v3C16 5.328 16.671 6 17.5 6zm10 3c.414.0.789-.168 1.06-.439l2-2C30.832 6.289 31 5.914 31 5.5 31 4.672 30.329 4 29.5 4c-.414.0-.789.168-1.061.44l-2 2C26.168 6.711 26 7.086 26 7.5 26 8.328 26.671 9 27.5 9zM6.439 8.561C6.711 8.832 7.086 9 7.5 9 8.328 9 9 8.328 9 7.5c0-.414-.168-.789-.439-1.061l-2-2C6.289 4.168 5.914 4 5.5 4 4.672 4 4 4.672 4 5.5c0 .414.168.789.439 1.06l2 2.001zM33.5 16h-3c-.828.0-1.5.672-1.5 1.5s.672 1.5 1.5 1.5h3c.828.0 1.5-.672 1.5-1.5S34.328 16 33.5 16zM28.561 26.439C28.289 26.168 27.914 26 27.5 26c-.828.0-1.5.672-1.5 1.5.0.414.168.789.439 1.06l2 2C28.711 30.832 29.086 31 29.5 31c.828.0 1.5-.672 1.5-1.5.0-.414-.168-.789-.439-1.061l-2-2zM17.5 29c-.829.0-1.5.672-1.5 1.5v3c0 .828.671 1.5 1.5 1.5s1.5-.672 1.5-1.5v-3C19 29.672 18.329 29 17.5 29zm0-22C11.71 7 7 11.71 7 17.5S11.71 28 17.5 28 28 23.29 28 17.5 23.29 7 17.5 7zm0 18c-4.136.0-7.5-3.364-7.5-7.5s3.364-7.5 7.5-7.5 7.5 3.364 7.5 7.5S21.636 25 17.5 25z"/></svg></label><label id=toggle-label-dark for=darkmode-toggle tabindex=-1><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" id="nightIcon" viewBox="0 0 100 100" style="enable-background='new 0 0 100 100'"><title>黑暗模式</title><path d="M96.76 66.458c-.853-.852-2.15-1.064-3.23-.534-6.063 2.991-12.858 4.571-19.655 4.571C62.022 70.495 50.88 65.88 42.5 57.5 29.043 44.043 25.658 23.536 34.076 6.47c.532-1.08.318-2.379-.534-3.23-.851-.852-2.15-1.064-3.23-.534-4.918 2.427-9.375 5.619-13.246 9.491-9.447 9.447-14.65 22.008-14.65 35.369.0 13.36 5.203 25.921 14.65 35.368s22.008 14.65 35.368 14.65c13.361.0 25.921-5.203 35.369-14.65 3.872-3.871 7.064-8.328 9.491-13.246C97.826 68.608 97.611 67.309 96.76 66.458z"/></svg></label></div><link rel=alternate type=application/rss+xml href=https://www.physician.tw/Pulmonology-Chronic-Obstructive-Pulmonary-Disease-Fast-Facts-NEJM-Resident-360/rss.xml title></header><article><h1>Pulmonology - Chronic Obstructive Pulmonary Disease - Fast Facts | NEJM Resident 360</h1><p class=meta>最後更新於
Feb 23, 2023
<a href=https://github.com/htlin222/garden/tree/hugo/content/Pulmonology%20-%20Chronic%20Obstructive%20Pulmonary%20Disease%20-%20Fast%20Facts%20%20NEJM%20Resident%20360.md rel=noopener>🪚 編輯原始文件</a></p><ul class=tags></ul><p>at: <a href=/inbox rel=noopener class=internal-link data-src=/inbox>inbox</a></p><a href=#pulmonology---chronic-obstructive-pulmonary-disease---fast-facts--nejm-resident-360><h1 id=pulmonology---chronic-obstructive-pulmonary-disease---fast-facts--nejm-resident-360><span class=hanchor arialabel=Anchor># </span>Pulmonology - Chronic Obstructive Pulmonary Disease - Fast Facts | NEJM Resident 360</h1></a><p>Chronic obstructive pulmonary disease (COPD) is characterized by persistent expiratory airflow limitation due to destruction of lung parenchyma and decrease in elastic recoil. COPD is associated with chronic airway and parenchymal inflammation, and the resultant airway obstruction leads to air trapping and hyperinflation. The decline in lung function in COPD is generally progressive.</p><p>The most important risk factor for developing COPD is cigarette smoking. An estimated 25% of individuals with a history of cigarette smoking develop COPD. Globally, inhalation of biomass fuel emissions is another important etiologic agent. The principal pathophysiological features of COPD are shown in following image.</p><a href=#pathophysiological-features-of-airflow-obstruction-in-chronic-obstructive-pulmonary-disease-copd><h3 id=pathophysiological-features-of-airflow-obstruction-in-chronic-obstructive-pulmonary-disease-copd><span class=hanchor arialabel=Anchor># </span>Pathophysiological Features of Airflow Obstruction in Chronic Obstructive Pulmonary Disease (COPD)</h3></a><p><strong>(Source: Outpatient Management of Severe COPD. N Engl J Med 2010.)</strong></p><a href=#assessment><h2 id=assessment><span class=hanchor arialabel=Anchor># </span>Assessment</h2></a><p>Although spirometry is needed to make a diagnosis of COPD (see Investigations below), evaluation of symptoms, exacerbation history and risk, and physical examination findings provide important clues.</p><p><strong>Presentation:</strong> COPD should be considered in anyone with the following symptoms:</p><ul><li><p>chronic cough</p></li><li><p>chronic sputum production</p></li><li><p>dyspnea</p></li><li><p>history of exposure to risk factors</p></li></ul><p>Patient symptoms can be rated using objective scales including:</p><ul><li><p>COPD Assessment Test (CAT): measures COPD symptoms (e.g., cough and shortness of breath) on a 0–40 scale, with a score of ≥10 indicating COPD symptoms that limit quality of life</p></li><li><p>Modified Medical Research Council (mMRC) Dyspnea Scale: scores the degree of breathlessness from 0–4, with 4 representing the highest degree of exercise intolerance</p></li></ul><p><strong>Exacerbation history:</strong> In addition to symptoms, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommends using the ABCD assessment tool to document exacerbation history, determine patient level of risk, and guide subsequent pharmacologic management. The following figure describes the GOLD Refined ABCD Assessment Tool.</p><a href=#the-refined-abcd-assessment-tool><h3 id=the-refined-abcd-assessment-tool><span class=hanchor arialabel=Anchor># </span>The Refined ABCD Assessment Tool</h3></a><p><strong>The numbers represent severity of airflow limitation (spirometric grades 1 to 4), and the letters (ABCD) represent symptom burden and risk of exacerbation.<br>(Reprinted with permission from the Global Strategy for Diagnosis, Management and Prevention of COPD 2020. © 2020 Global Initiative for Chronic Obstructive Lung Disease, all rights reserved.)</strong></p><p><strong>Prognostic factors:</strong> The BODE index (<strong>B</strong>ody-mass index, airflow <strong>O</strong>bstruction, <strong>D</strong>yspnea, and <strong>E</strong>xercise) is a simple, multidimensional grading system that incorporates the patient’s BMI, degree of airflow obstruction (FEV<sub>1</sub>), subjective dyspnea symptoms (mMRC Dyspnea Scale), and exercise capacity (6-minute walking distance). The BODE index can be used to predict the risk of death from any cause and from respiratory causes in patients with COPD. The score ranges from 0–10; for every 1-point increase in the BODE index, the hazard ratio for all-cause mortality increases by 1.34 and for respiratory-related mortality by 1.62.</p><p><strong>Physical exam:</strong> A number of physical exam findings can hint at an underlying diagnosis of COPD. These findings are a manifestation of airway obstruction, hyperinflation, and chronic hypoxemia. Patients may present with varying degrees of tachypnea, respiratory muscle use, and pursed-lip breathing.</p><ul><li><p><strong>Hyperinflation:</strong> On examination, patients may appear cachectic from increased respiratory efforts. An increased anteroposterior-to-lateral diameter >0.9 is indicative of hyperinflation (barrel-shaped chest).</p></li><li><p><strong>Wheeze:</strong> On auscultation, diminished breath sounds may be heard due to decreased airflow. Auscultated wheeze has a high-positive-likelihood ratio for the diagnosis of COPD.</p></li><li><p><strong>Cyanosis:</strong> Examination of the hands may reveal cyanosis or nicotine staining.</p></li></ul><p>For more information on the value of the physical exam in the diagnosis of airway obstruction, see this review. </p><a href=#investigations><h3 id=investigations><span class=hanchor arialabel=Anchor># </span>Investigations</h3></a><p><strong>Spirometry:</strong> A spirometry measurement of the <strong>ratio of postbronchodilator forced expiratory volume in 1 second [FEV <sub>1</sub>] to forced vital capacity (FEV</strong>**<sub>1</sub>****/FVC) &lt;0.7** is typically consistent with the diagnosis of COPD. GOLD classifies the severity of COPD based on the following spirometric measurements:</p><a href=#gold-classification-of-airflow-limitation-severity><h3 id=gold-classification-of-airflow-limitation-severity><span class=hanchor arialabel=Anchor># </span>GOLD Classification of Airflow Limitation Severity</h3></a><table><thead><tr><th>Category</th><th>Symptoms</th><th>Postbronchodilator FEV<sub>1</sub></th></tr></thead><tbody><tr><td>1</td><td>Mild</td><td>>80% of predicted</td></tr><tr><td>2</td><td>Moderate</td><td>50% to &lt;80% of predicted</td></tr><tr><td>3</td><td>Severe</td><td>30% to &lt;50% of predicted</td></tr><tr><td>4</td><td>Very severe</td><td>&lt;30% of predicted</td></tr></tbody></table><a href=#reference-pocket-guide-to-copd-diagnosis-management-and-prevention-global-initiative-for-chronic-obstructive-lung-disease-gold-2020><h6 id=reference-pocket-guide-to-copd-diagnosis-management-and-prevention-global-initiative-for-chronic-obstructive-lung-disease-gold-2020><span class=hanchor arialabel=Anchor># </span>(Reference: Pocket Guide to COPD Diagnosis, Management, and Prevention, Global Initiative for Chronic Obstructive Lung Disease [GOLD] 2020.)</h6></a><a href=#initial-treatment><h2 id=initial-treatment><span class=hanchor arialabel=Anchor># </span>Initial Treatment</h2></a><p><strong>Smoking cessation:</strong> The importance of smoking cessation should be a key discussion with COPD patients because it has been associated with mortality reduction. See Smoking Cessation in the Ambulatory Care rotation guide.</p><p><strong>Bronchodilators:</strong> First-line pharmacologic agents for treatment of COPD are inhaled <strong>bronchodilators</strong> (beta<sub>2</sub>-agonist or anticholinergics) alone, in combination, or with the addition of <strong>inhaled glucocorticoids, depending on the patient&rsquo;s symptoms</strong>. The use of bronchodilators and inhaled glucocorticoids is associated with a reduction in exacerbations and hospitalizations and improvement in FEV<sub>1</sub> decline. A growing body of evidence suggests that inhaled glucocorticoids are more effective in patients who have high blood eosinophil levels than in patient who do not.</p><a href=#initial-pharmacologic-management-of-copd-patients-based-on-risk><h3 id=initial-pharmacologic-management-of-copd-patients-based-on-risk><span class=hanchor arialabel=Anchor># </span>Initial Pharmacologic Management of COPD Patients Based on Risk</h3></a><p><strong>Abbreviations: LAMA, long-acting muscarinic antagonists; LABA, long-acting beta<sub>2</sub>-agonists; ICS, inhaled corticosteroids<br>(Source: Global Strategy for Diagnosis, Management and Prevention of COPD 2020. © 2020 Global Initiative for Chronic Obstructive Lung Disease, all rights reserved).</strong></p><p><strong>Supplemental oxygen:</strong> The use of supplemental oxygen is associated with reduced mortality but is indicated only if partial pressure of oxygen is ≤55 mm Hg or oxygen saturation is ≤88% while respiring ambient air. Patients with COPD and moderate desaturation (resting oxygen saturation of 89% to 93% or moderate exercise-induced desaturation) do not appear to benefit from supplemental oxygen.</p><p><strong>Chronic macrolide therapy:</strong> In former smokers, chronic macrolide therapy with azithromycin has been shown to prevent COPD exacerbations and improve symptoms. This treatment can be considered in patients with persistent symptoms despite optimal inhaled therapy.</p><p>A simplified algorithm for the initial assessment and management of patients with COPD is provided below:</p><a href=#algorithm-for-the-evaluation-and-treatment-of-persons-with-copd-or-at-risk-for-copd><h3 id=algorithm-for-the-evaluation-and-treatment-of-persons-with-copd-or-at-risk-for-copd><span class=hanchor arialabel=Anchor># </span>Algorithm for the Evaluation and Treatment of Persons with COPD or at Risk for COPD</h3></a><p><strong>(Source: Update on Clinical Aspects of Chronic Obstructive Pulmonary Disease. N Engl J Med 2019.)</strong></p><a href=#copd-exacerbation><h2 id=copd-exacerbation><span class=hanchor arialabel=Anchor># </span><strong>COPD Exacerbation</strong></h2></a><p>COPD exacerbation is the acute change in baseline dyspnea, cough, and/or sputum beyond day-to-day variation that necessitates a change in therapy. Exacerbations are associated with reduced lung function and quality of life and increased morbidity and mortality. Exacerbations are typically associated with respiratory infections caused by viral and bacterial triggers, as described in the following table:</p><p><strong>(Source: Infection in the Pathogenesis and Course of Chronic Obstructive Pulmonary Disease. N Engl J Med 2008.)</strong></p><p><strong>Treatment of COPD Exacerbations:</strong></p><ul><li><p><strong>Glucocorticoids</strong> are associated with a reduction in hospitalization and treatment failure in patients with COPD exacerbations.</p></li><li><p><strong>Antibiotics</strong> are also frequently prescribed for management of COPD exacerbations, especially those associated with increased purulence of sputum. Chronic macrolide therapy is associated with a reduction in COPD exacerbations.</p></li></ul><p><em>See the GOLD Pocket Guide to COPD Diagnosis, Management, and Prevention, 2020 Report for a summary of the diagnosis and outpatient management of COPD.</em></p><p><a href=/inbox rel=noopener class=internal-link data-src=/inbox>inbox</a></p></article><hr><div class=page-end id=footer><div class=backlinks-container><h3>↩️ 反向連結</h3><ul class=backlinks><li><a href=/all-list-of-resident360/ data-ctx="Pulmonology - Chronic Obstructive Pulmonary Disease - Fast Facts  NEJM Resident 360" data-src=/all-list-of-resident360 class=internal-link>all list of resident360</a></li><li><a href=/chest/ data-ctx="Pulmonology - Chronic Obstructive Pulmonary Disease - Fast Facts  NEJM Resident 360" data-src=/chest class=internal-link>pulmonology</a></li><li><a href=/pulm/ data-ctx="Pulmonology - Chronic Obstructive Pulmonary Disease - Fast Facts  NEJM Resident 360" data-src=/pulm class=internal-link>pulmonology</a></li><li><a href=/pulm-2/ data-ctx="Pulmonology - Chronic Obstructive Pulmonary Disease - Fast Facts  NEJM Resident 360" data-src=/pulm-2 class=internal-link>pulmonology</a></li><li><a href=/pulmonology/ data-ctx="Pulmonology - Chronic Obstructive Pulmonary Disease - Fast Facts  NEJM Resident 360" data-src=/pulmonology class=internal-link>pulmonology</a></li><li><a href=/recent/ data-ctx="Pulmonology - Chronic Obstructive Pulmonary Disease - Fast Facts  NEJM Resident 360" data-src=/recent class=internal-link>recent</a></li></ul></div><div><script async src=https://cdn.jsdelivr.net/npm/d3@6.7.0/dist/d3.min.js integrity="sha256-+7jaYCp29O1JusNWHaYtgUn6EhuP0VaFuswhNV06MyI=" crossorigin=anonymous></script><h3>🤯互動圖</h3><div id=graph-container></div><style>:root{--g-node:var(--secondary);--g-node-active:var(--primary);--g-node-inactive:var(--visited);--g-link:var(--outlinegray);--g-link-active:#5a7282}</style><script src=https://www.physician.tw/js/graph.2d9e48dbe7ea47c0ef1c58296ce14448.js></script></div></div><div><div id=disqus_thread></div><script type=application/javascript>window.disqus_config=function(){},function(){if(["localhost","127.0.0.1"].indexOf(window.location.hostname)!=-1){document.getElementById("disqus_thread").innerHTML="Disqus comments not available by default when the website is previewed locally.";return}var t=document,e=t.createElement("script");e.async=!0,e.src="//physician.disqus.com/embed.js",e.setAttribute("data-timestamp",+new Date),(t.head||t.body).appendChild(e)}()</script><noscript>Please enable JavaScript to view the <a href=https://disqus.com/?ref_noscript>comments powered by Disqus.</a></noscript><a href=https://disqus.com class=dsq-brlink>comments powered by <span class=logo-disqus>Disqus</span></a></div><div id=contact_buttons><footer><p>本網站是由 Hsieh-Ting Lin 以❤️ 用 <a href=https://github.com/jackyzha0/quartz>Quartz</a>這個酷東西種出來🪴 , © 2024</p><p><a href=https://www.buymeacoffee.com/htl.lizard><img src=https://cdn.buymeacoffee.com/buttons/v2/default-yellow.png width=200></a></p><ul><li><a href=https://www.physician.tw/>🏠首頁</a></li><li><a href=https://www.facebook.com/htlin.lizard>Facebook</a></li><li><a href=https://twitter.com/htlin222>Twitter</a></li><li><a href=https://github.com/htlin222>GitHub</a></li><li><a href=https://htlin.site>Blog</a></li><li><a href=https://htlin222.medium.com>Medium</a></li></ul></footer></div></div></body></html>